Cellectis (Paris: ALCLS) (Alternext: ALCLS) (NASDAQ: CLLS)a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France.
CLLS lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM.
CLLS has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia.
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
May 16, 2020 - 12:13pm |
Out and About, Research Notes, Out and About, Earnings Q1
Athersys (ATHX), Homology Medicine (FIXX), Verastem (VSTM), EDITAS Medicine (EDIT), REGENXBIO (RGNX), Caladius Biosciences (CLBS), Bellicum Pharmaceuticals (BLCM),, uniQure (QURE), CRISPR Therapeutics (CRSP),Aduro Biotech (ADRO), Brainstorm Cell Therapeutics (BCLI), Editas medicine (EDIT), Global Blood Therapeutics (GBT), Inyellia Therapeutics (NTLA), Ionis Pharmaceuticals (IONS), Ultragenyx (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), MiMedx (MDXG), Stemline Therapeutics (STML) acquired by Menarini, an Italian pharma, Fate therapeutics (FATE), Sangamo Therapeutics (SGMO), bluebird bio (BLUE), BioLife Solutions BLFS, Biostage (BSTG), Pluristem (PSTI)
- May 11, 2020 - 2:08pm | Research Notes
- April 11, 2020 - 1:23pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
- November 3, 2019 - 2:45pm | Out and About, Research Notes, Out and About, Earnings
- January 29, 2019 - 12:50pm | Out and About, Out and About
- September 11, 2018 - 1:18pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q2
- June 2, 2018 - 7:11am | Out and About, Out and About, Earnings, Earnings Q1
- May 16, 2018 - 5:58pm | Financings
- April 4, 2018 - 8:56pm | Out and About, Out and About, Financings
- April 3, 2018 - 8:31am | Out and About, Research Notes, Out and About
- March 10, 2018 - 9:22am | Earnings, Earnings Q4
- March 4, 2018 - 11:11am | Analysis, Out and About
- November 3, 2017 - 1:08pm | Earnings, Earnings Q3
- May 5, 2017 - 8:59am | Earnings, Earnings Q1
- March 27, 2017 - 12:52pm | Out and About, Research Notes
- March 10, 2017 - 12:00am | Earnings, Earnings Q4
- February 9, 2017 - 1:13pm | Research Notes
- February 7, 2017 - 12:42pm | Research Notes
- November 2, 2016 - 8:46pm | Earnings, Earnings Q3
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2